More on Ponatinib and Next Steps - Harry Erba, MD
http://www.youtube.c...h?v=pmxzWZVzdMg
Published on Nov 7, 2013
Harry Erba, MD, Director of the Hematological Malignancies Program at the University of Alabama at Birmingham shares more insights into the latest news on Iclusig (Ponatinib) and important information for the days ahead. He shares some background information on the drug's efficacy in CML treatment and discusses the process of submitting the individual Investigational New Drug (IND) application that will be required to access the drug.